首页|期刊导航|临床眼科杂志|泛黄斑区阈值下微脉冲激光联合康柏西普治疗糖尿病性黄斑水肿后的黄斑区血流变化

泛黄斑区阈值下微脉冲激光联合康柏西普治疗糖尿病性黄斑水肿后的黄斑区血流变化OA

Changes in macular blood flow density after Conbercept combined with pan-macular subthreshold micro-pulse laser for diabetic macular edema

中文摘要英文摘要

目的 探讨泛黄斑区阈值下微脉冲激光(SMPL)联合康柏西普治疗糖尿病性黄斑水肿(DME)的黄斑区血流变化.方法 前瞻性随机对照研究.收集2022年1月至2024年12月在合肥市第二人民医院眼科确诊为DME的患者.随机分为泛黄斑区SMPL联合康柏西普治疗组(联合组)和单纯康柏西普治疗组(单纯组).采集并比较两组治疗前(基线)和治疗3个月及6个月随访时的最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT),以及相干光层析血管成像术(OCTA)参数,包括黄斑中心凹无血管区(FAZ)面积、使用17分区ETDRS环划分后极部黄斑区视网膜,记录并比较各分区的浅层毛细血管丛血管密度(SCPVD)及深层毛细血管丛血管密度(DCPVD),治疗6个月时玻璃体腔注射康柏西普次数,以及泛黄斑区SMPL治疗次数.使用独立样本t检验、重复测量方差分析及Mann-Whitney U检验进行统计学分析.结果 共纳入DME患者45例(56只眼),其中男性20例(26只眼),女性25例(30只眼),单纯组24例(30只眼),联合组21例(26只眼),两组基线特征比较,差异均无统计学意义(均P>0.05).治疗3个月和6个月随访时,与基线比较,两组BCVA均显著改善(均P<0.05),logMAR BCVA联合组提高至0.58±0.31及0.55±0.32,单纯组提高至0.63±0.23及0.61±0.27,两组视力提高程度,差异无统计学意义(均P>0.05);CMT均显著下降(均 P<0.05),联合组降低至(305.51±74.62)μm及(283.51±62.08)μm,单纯组降低至(328.23±84.58)μm 及(312.51±86.85)μm(均P<0.05),两组CMT降低程度差异均无统计学意义(均P>0.05);FAZ面积均明显下降(均P<0.05),联合组缩小至(0.38±0.08)mm2及(0.35±0.08)mm2,单纯组缩小至(0.42±0.11)mm2及(0.37±0.09)mm2,两组FAZ面积缩小程度差异无统计学意义(均P>0.05);浅层毛细血管丛血管密度,单纯组SCPVD-T4在治疗后3个月及6个月,均较基线明显下降(均P<0.05);深层毛细血管丛血管密度,治疗后6个月,联合组DCPVD-T3较基线显著提高(P<0.05),单纯组DCPVD-T4较基线显著下降(P<0.05);眼内注射药物次数,治疗6个月时,单纯组为4(3,4)次,联合组为3(3,4)次,联合组显著低于单纯组(P<0.05).SMPL治疗次数,联合组为1(1,2);两组患者随访期间,无全身或局部严重不良反应发生.结论 泛黄斑区SMPL联合康柏西普治疗DME患者有效且安全,与单纯康柏西普注射治疗相比,可减少眼内注药次数、维持及改善视网膜毛细血管丛的血流灌注.

Objective To investigate changes in macular blood flow density after Conbercept combined with pan-macular subthreshold micropulse laser in the treatment of diabetic macular edema(DME).Methods This prospective randomized controlled study enrolled patients who were diagnosed with DME at the Department of Ophthalmology in the Second People's Hospital of Hefei from January 2022 to December 2024.Patients were randomized to the Conbercept monotherapy group or the pan-macular subthreshold micropulse laser(SMPL)combined with Conbercept group.The best-corrected visual acuity(BCVA),central macular thickness(CMT),and optical coherence tomography angiography param-eters,including superficial capillary plexus vessel density(SCPVD),deep capillary plexus vessel density(DCPVD),and fo-veal avascular zone(FAZ)area were compared at baseline and at 3 and 6 months after the treatment.The numbers of intra-vitreal injections and SMPL treatments during the 6-month follow-up were recorded.Statistical analyses included the independent-sample t test,chi-square test,repeated-measures analysis of variance with LSD-t post hoc comparisons,and the Mann-Whitney U test.Results Forty-five patients(56 eyes)were enrolled,including 20 males(26 eyes)and 25 fe-males(30 eyes).The monotherapy group included 24 patients(30 eyes),and the combination group included 21 patients(26 eyes).There was no significant difference in baseline characteristics between the two groups(all P>0.05).At 3 and 6 months after the treatment,logMAR BCVA improved significantly in both groups(all P<0.05),reaching 0.58±0.31 and 0.55±0.32 in the combination group and 0.63±0.23 and 0.61±0.27 in the monotherapy group,respectively.There were no significant differences between groups(all P>0.05).CMT decreased significantly in both groups(all P<0.05),reaching(305.51±74.62)μm and(283.51±62.08)μm in the combination group and(328.23±84.58)μm and(312.51±86.85)μm in the monotherapy group,respectively.There were no significant differences between groups(all P>0.05).FAZ area de-creased significantly in both groups(all P<0.05),reaching(0.38±0.08)mm2 and(0.35±0.08)mm2 in the combination group and(0.42±0.11)mm2 and(0.37±0.09)mm2 in the monotherapy group,respectively.There were no significant differences be-tween groups(all P>0.05).SCPVD-T4 in the monotherapy group decreased significantly from baseline at both 3 and 6 months after the treatment(all P<0.05).At 6 months after the treatment,DCPVD-T3 in the combination group increased sig-nificantly from baseline,whereas DCPVD-T4 in the monotherapy group decreased significantly from baseline(all P<0.05).The monotherapy group received 4(3,4)intravitreal injections,whereas the combination group received 3(3,4)injections.The number of injections was significantly lower in the combination group(P<0.05).The number of SMPL treatments in the combination group was 1(1,2).No severe systemic or ocular adverse events occurred during follow-up.Conclusions Pan-macular subthreshold micropulse laser combined with Conbercept is effective and safe for treating DME.Compared with Conbercept monotherapy,the combination treatment reduces the number of intravitreal injections and helps maintain and improve retinal capillary plexus perfusion.

魏科;纪风涛;王慧;李永蓉;刘广源;戴维;廖荣丰

230011 安徽合肥,合肥市第二人民医院(安徽医科大学附属合肥医院)眼科230011 安徽合肥,合肥市第二人民医院(安徽医科大学附属合肥医院)眼科230011 安徽合肥,合肥市第二人民医院(安徽医科大学附属合肥医院)眼科230011 安徽合肥,合肥市第二人民医院(安徽医科大学附属合肥医院)眼科230011 安徽合肥,合肥市第二人民医院(安徽医科大学附属合肥医院)眼科230011 安徽合肥,合肥市第二人民医院(安徽医科大学附属合肥医院)眼科230022 安徽合肥,安徽医科大学第一附属医院眼科

糖尿病视网膜病变黄斑水肿激光凝固术康柏西普相干光层析血管成像术

Diabetic retinopathyMacular edemaLaser coagulationConberceptOptical coherence tomography angiography

《临床眼科杂志》 2026 (4)

289-296,8

合肥市卫生健康应用医学研究项目(Hwk2022zd008)合肥市第二人民医院科研项目(2022yzd002)

10.3969/j.issn.1006-8422.2026.04.001

评论